Table 1.

Characteristics of 76 evaluable patients

Characteristics	Total = 76 cases
Age	56.4 ± 1.3 years
Sex
Male	54 (71%)
Female	22 (29%)
Clinical T stage
cT3	69 (91%)
cT4	7 (9%)
Clinical N stage
cN0	17 (22%)
cN+	59 (78%)
Clinical M stage
cM0	69 (91%)
cM1	7 (9%)
Staging pelvic disease includes
Transrectal ultrasound (TRUS)	45
Magnetic resonance imaging (MRI)	37
Both TRUS and MRI	15
Neither (CT and clinical findings only)	9
PROSPECT eligible?*
Y	38 (50%)
N	38 (50%)
Clinical score†
CS0	18 (24%)
CS1	48 (63%)
CS2	10 (13%)

Abbreviations: CT = computed tomography; 5FU = 5-fluorouracil; RT = radiation therapy.

^*Clinical score (CS) based on 4 adverse pretreatment findings: site <5 cm from verge, tethered or fixed to palpation, circumferential, near obstructing. CS0: 0 adverse factors; CS1: 1or 2 adverse factors; CS2: 3 or 4 adverse factors.

^†PROSPECT eligible: disease extent eligible for recently activated (N1048) trial (comparing preoperative RT+5FU vs FOLFOX): location at ≥5 cm, no disease ≤3 mm from mesorectal fascia, and cT <cT4.